HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Checkpoint inhibition and rheumatic events: ‘Many more questions than answers’
-
- Choosing quality cancer care: The effect of branding John Sweetenham, MD, FRCP, FACP
- ‘Cancer-agnostic’ NTRK inhibitor approval ushers in paradigm of personalized genomics-guided therapeutics Patrick C. Ma, MD, MSc
- Shorter chemotherapy course 'equally effective' in diffuse large B-cell lymphoma
- Trial reveals ‘very small’ differences between accelerated partial breast irradiation, whole breast irradiation for early-stage cancer
- Adverse effects from certain immunotherapies may be more common than initially reported
- Low-cost genetic test spurs ‘cascade testing’ among relatives
- Cetuximab plus FOLFOX-4 safe, effective in metastatic colorectal cancer
- Prostatectomy plus radiotherapy may improve survival in advanced prostate cancer
-
- FDA approves Truxima, first biosimilar for adults with non-Hodgkin lymphoma
- FDA approves Tecentriq-based combination for first-line treatment of lung cancer
- FDA approves Xospata for relapsed, refractory FLT3-mutated acute myeloid leukemia